Therapeutic area intelligence for Sickle Cell Disease with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Recent signals(4)

ClinicalJuly 26, 2026

Blood Sampling Study for Sickle Cell Disease Research Initiated by NIDDK

A study has been launched to collect blood samples from individuals with unique red blood cell features related to sickle cell disease.

ClinicalJuly 21, 2026

Phase 1 Trial of VAS-101 Gel for Improved Curcumin Absorption in Sickle Cell Disease

A clinical trial is underway to evaluate the efficacy of VAS-101, a skin gel containing curcumin, in patients with stable sickle cell disease.

StrategyJuly 8, 2026

Study to Enhance Hydroxyurea Adoption for Sickle Cell Disease in Nigeria

A study aims to improve hydroxyurea adoption for sickle cell disease in Nigeria, addressing significant provider-level barriers.

ClinicalJuly 6, 2026

Gerofit Exercise Intervention Study for Sickle Cell Disease Shows Promise

The SICKLE-FIT study aims to evaluate a personalized exercise program for older adults with sickle cell disease.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Sickle Cell Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.